Brought to you by 
AmpliPhi, Intrexon develop bacteriophage-based treatments for infectious diseases
03 Oct 2017
Executive Summary
Infectious disease-focused AmpliPhi BioSciences Corp. and synthetic biology specialist Intrexon Corp. agreed to develop new bacteriophage-containing therapies aimed at antibiotic-resistant infections.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AmpliPhi, Intrexon develop bacteriophage-based treatments for infectious diseases
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice